Royalty Pharma plc (RPRX)
- Previous Close
33.10 - Open
33.22 - Bid 33.00 x 100
- Ask 33.17 x 100
- Day's Range
33.08 - 33.72 - 52 Week Range
24.05 - 34.20 - Volume
1,463,744 - Avg. Volume
4,650,114 - Market Cap (intraday)
18.998B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
13.50 - EPS (TTM)
2.45 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield 0.88 (2.69%)
- Ex-Dividend Date May 16, 2025
- 1y Target Est
39.74
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
www.royaltypharma.comRecent News: RPRX
View More
Performance Overview: RPRX
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPRX
View MoreValuation Measures
Market Cap
14.35B
Enterprise Value
20.15B
Trailing P/E
14.32
Forward P/E
10.65
PEG Ratio (5yr expected)
2.32
Price/Sales (ttm)
8.62
Price/Book (mrq)
1.47
Enterprise Value/Revenue
8.90
Enterprise Value/EBITDA
10.00
Financial Highlights
Profitability and Income Statement
Profit Margin
37.95%
Return on Assets (ttm)
4.67%
Return on Equity (ttm)
13.03%
Revenue (ttm)
2.26B
Net Income Avi to Common (ttm)
858.98M
Diluted EPS (ttm)
2.45
Balance Sheet and Cash Flow
Total Cash (mrq)
987.23M
Total Debt/Equity (mrq)
73.60%
Levered Free Cash Flow (ttm)
-1.76B
Research Analysis: RPRX
View MoreResearch Reports: RPRX
View MoreRoyalty Pharma Earnings: Impressive Portfolio Growth and Share Repurchases Instill Confidence
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice TargetRoyalty Pharma's Strong Portfolio Growth and Manager Acquisition Boost Long-Term Outlook
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice TargetRoyalty Pharma Earnings: Solid Growth; Diverse Portfolio Supports Positive Long-Term Outlook
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
RatingPrice TargetMid Cap U.S. Pick List January 2025
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.